Cargando…
Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome
AIM: The primary treatment for the subset of infantile hemangiomas (IHs) which develops complication is pharmacological intervention, and propranolol has become a popular choice. Here, we evaluated the efficacy and safety of propranolol in a clinical cohort of IHs and analyzed clinical characteristi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6568152/ https://www.ncbi.nlm.nih.gov/pubmed/31258264 http://dx.doi.org/10.4103/jiaps.JIAPS_12_18 |
_version_ | 1783427205428150272 |
---|---|
author | Ainipully, Arun Mohanan Narayanan, Sarath Kumar Vazhiyodan, Arun Preeth Somnath, Prathap |
author_facet | Ainipully, Arun Mohanan Narayanan, Sarath Kumar Vazhiyodan, Arun Preeth Somnath, Prathap |
author_sort | Ainipully, Arun Mohanan |
collection | PubMed |
description | AIM: The primary treatment for the subset of infantile hemangiomas (IHs) which develops complication is pharmacological intervention, and propranolol has become a popular choice. Here, we evaluated the efficacy and safety of propranolol in a clinical cohort of IHs and analyzed clinical characteristics associated with a good outcome. MATERIALS AND METHODS: We retrospectively reviewed a total of 52 IHs patients, between ages 1 and 48 months (median age: 7.5 months), who were treated with oral propranolol, with dose ranging from 2 to 3 mg/kg/day. Efficacy was evaluated using mean percentage reduction, visual analog scale (VAS), and parental satisfaction levels at week 2 and months 1, 2, 6, and 12. The adverse effects were noted and responses after 6 months were graded. Statistical analyses of the outcome were also performed for the responses with regard to age at propranolol initiation, site of lesion, and mean duration of treatment. RESULTS: A therapeutic response with at least 50% mean percentage reduction in size was noted in 84.6% at the end of 6 months. VAS score and parental satisfaction levels correlated well with mean percentage reduction (63.7 ± 15.6) at 6 months. Patients aged <6 months and those with cephalic lesions exhibited a greater therapeutic response rate with shorter overall mean duration of the treatment. CONCLUSIONS: Oral propranolol at 2–3 mg/kg/day dosing has shown to be effective and safe for IHs in pediatric age group. Intervention in the early proliferative phase, with especially, the cephalic lesions result in better resolution rates with shorter duration of overall treatment. |
format | Online Article Text |
id | pubmed-6568152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-65681522019-07-01 Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome Ainipully, Arun Mohanan Narayanan, Sarath Kumar Vazhiyodan, Arun Preeth Somnath, Prathap J Indian Assoc Pediatr Surg Original Article AIM: The primary treatment for the subset of infantile hemangiomas (IHs) which develops complication is pharmacological intervention, and propranolol has become a popular choice. Here, we evaluated the efficacy and safety of propranolol in a clinical cohort of IHs and analyzed clinical characteristics associated with a good outcome. MATERIALS AND METHODS: We retrospectively reviewed a total of 52 IHs patients, between ages 1 and 48 months (median age: 7.5 months), who were treated with oral propranolol, with dose ranging from 2 to 3 mg/kg/day. Efficacy was evaluated using mean percentage reduction, visual analog scale (VAS), and parental satisfaction levels at week 2 and months 1, 2, 6, and 12. The adverse effects were noted and responses after 6 months were graded. Statistical analyses of the outcome were also performed for the responses with regard to age at propranolol initiation, site of lesion, and mean duration of treatment. RESULTS: A therapeutic response with at least 50% mean percentage reduction in size was noted in 84.6% at the end of 6 months. VAS score and parental satisfaction levels correlated well with mean percentage reduction (63.7 ± 15.6) at 6 months. Patients aged <6 months and those with cephalic lesions exhibited a greater therapeutic response rate with shorter overall mean duration of the treatment. CONCLUSIONS: Oral propranolol at 2–3 mg/kg/day dosing has shown to be effective and safe for IHs in pediatric age group. Intervention in the early proliferative phase, with especially, the cephalic lesions result in better resolution rates with shorter duration of overall treatment. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6568152/ /pubmed/31258264 http://dx.doi.org/10.4103/jiaps.JIAPS_12_18 Text en Copyright: © 2019 Journal of Indian Association of Pediatric Surgeons http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Ainipully, Arun Mohanan Narayanan, Sarath Kumar Vazhiyodan, Arun Preeth Somnath, Prathap Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome |
title | Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome |
title_full | Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome |
title_fullStr | Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome |
title_full_unstemmed | Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome |
title_short | Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome |
title_sort | oral propranolol in infantile hemangiomas: analysis of factors that affect the outcome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6568152/ https://www.ncbi.nlm.nih.gov/pubmed/31258264 http://dx.doi.org/10.4103/jiaps.JIAPS_12_18 |
work_keys_str_mv | AT ainipullyarunmohanan oralpropranololininfantilehemangiomasanalysisoffactorsthataffecttheoutcome AT narayanansarathkumar oralpropranololininfantilehemangiomasanalysisoffactorsthataffecttheoutcome AT vazhiyodanarunpreeth oralpropranololininfantilehemangiomasanalysisoffactorsthataffecttheoutcome AT somnathprathap oralpropranololininfantilehemangiomasanalysisoffactorsthataffecttheoutcome |